Mayo Clinic researchers collaborated on a new study showing that the drug abemaciclib improves survival for people with high-risk, early-stage breast cancer. In the phase 3 monarchE trial, two years of abemaciclib (Verzenio) plus endocrine therapy reduced the risk of death by 15.8%
